Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING)

PHASE4CompletedINTERVENTIONAL
Enrollment

361

Participants

Timeline

Start Date

November 1, 2016

Primary Completion Date

April 15, 2022

Study Completion Date

April 15, 2022

Conditions
Smoking CessationGenetic Predisposition
Interventions
DRUG

Varenicline Tartrate or bupropion

the drug treatment will be chosen related to the polymorphism. If the polymorphism is favorable to varenicline the patient will receive varenicline, If it is favorable to bupropion the patient will receive bupropion, if not favorable to varenicline and bupropion the patient will receive bupropion + varenicline. If the patient has both favorable polymorphisms he will receive bupropion. Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.

Trial Locations (1)

05403000

Ambulatório de Tratamento Tabagismo - Incor HCFMUSP, São Paulo

All Listed Sponsors
collaborator

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

lead

University of Sao Paulo General Hospital

OTHER

NCT03362099 - Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING) | Biotech Hunter | Biotech Hunter